INTRODUCTION
Acute inflammation resulting in septic shock and multiorgan dysfunction (MOD) is a common cause of death in intensive care units (Hotchkiss and Karl, 2003) . Sepsis is a systemic inflammatory response occurring after massive bacterial infection or severe trauma, and in addition to septic shock and MOD, it can cause other complications such as adult respiratory distress syndrome (ARDS) (Cohen, 2002) . Despite advances in antimicrobial treatment and supportive therapy, mortality remains high in septic patients (Hotchkiss and Karl, 2003) .
During microbial infections, pathogen-associated molecular patterns (PAMPs) are recognized by the host defense system, which mounts a protective response (Cohen, 2002) . A similar response is triggered by endogenous mediators, which are released by necrotic cells during trauma (Karin et al., 2006) . The initial inflammatory reaction is amplified, and once amplification becomes excessive, shock and MOD can occur (Cohen, 2002) . Myeloid cells are critical for PAMP recognition and initiation and amplification of the inflammatory cascade, mainly through transcriptional regulation of genes encoding key inflammatory mediators, such as the cytokines TNF-a and IL1b (Dinarello, 1997) . In endotoxic shock TNF-a and IL-1b are released rapidly (after 30-90 min of onset) (Dinarello, 1997) and activate a secondary inflammatory cascade, dependent on transcription factor NF-kB (Ghosh and Karin, 2002) . More recently, a novel system termed the inflammasome, involved in posttranscriptional control of inflammation and innate immunity, has been described (Martinon and Tschopp, 2004) . The inflammasome system is based on ligand-dependent activation of caspase-1 (also termed interleukin-1b-converting enzyme [ICE] ) and other proinflammatory caspases that carry out processing of cytoplasmatic pro-IL-1b and pro-IL-18 (Martinon and Tschopp, 2004) . It is presently unclear whether the NF-kB and inflammasome systems interact, other than through the synthesis of pro-IL-1b, which is transcriptionally regulated by NF-kB.
One way to inhibit NF-kB activation is to use smallmolecule inhibitors of IKKb , one of the two catalytic subunits of the IKK complex, which is critical for NF-kB activation during acute inflammation (Chen et al., 2003) . IKK/NF-kB blockade has been proposed as a therapeutic modality for preventing mortality in septic shock and MOD (Zingarelli, 2005) . However, there are certain potential complications associated with this approach, such as a marked increase in susceptibility to apoptosis (Chen et al., 2003; Kisseleva et al., 2006) or perhaps a failure to induce negative regulators, such as A20 (Lee et al., 2000) . In addition, NF-kB plays a central role in activation of the host defense system (Li and Verma, 2002) , and therefore IKK inhibition can increase susceptibility to infections. In fact, certain pathogens, such as Yersinia pestis, inhibit IKK activation to evade host defense (Orth et al., 2000) .
To examine whether IKKb inhibition might prevent septic shock, we have conditionally disrupted the Ikkb gene in myeloid cells, and subjected the resultant mice, termed Ikkb Dmye , to endotoxin challenge. Surprisingly, Ikkb Dmye mice were more susceptible to endotoxin-induced mortality and showed significantly increased levels of circulating IL-1b, due to enhanced pro-IL-1b processing. Enhanced IL-1b secretion in myeloid IKKb-deficient mice was also seen upon bacterial infection. Prolonged pharmacological inhibition of IKKb, which interferes with NF-kB activation in the whole animal, also increased lipopolysaccharide (LPS)-induced mortality and plasma IL-1b. Thus, our studies, which uncovered an unexpected role for IKKb-driven NF-kB in the negative control of IL-1b secretion, strongly suggest that the therapeutic use of IKKb inhibitors may result in unintended effects on the host response. Enhanced secretion of IL-1b and similarly regulated cytokines by NFkB-deficient myeloid cells may have evolved as a protective strategy that provides innate immunity to microbes that produce NF-kB inhibitors.
RESULTS

Mice Lacking Myeloid IKKb Are Hypersusceptible to Endotoxic Shock
To examine the impact of myeloid-specific IKKb inhibition on endotoxic shock, we crossed LysM-Cre mice (Clausen et al., 1999) to ''floxed'' Ikkb mice to delete Ikkb alleles in macrophages and neutrophils. The resulting mice, termed Ikkb Dmye , lack IKKb protein and kinase activity, resulting in defective NF-kB activation only in myeloid cells, with no overt changes in the overall histology of lymphoid organs and other sites rich in myeloid cells, such as the gastrointestinal tract and liver (see Figure S1 in the Supplemental Data, available with this article online) (Arkan et al., 2005; Greten et al., 2004 Figure 1A ). Enhanced LPS toxicity in Ikkb Dmye mice correlated with both a marked increase in plasma IL-1b levels within the first 2 hr ( Figure 1B ) and modestly elevated plasma TNF-a ( Figure 1C) , whereas there was no difference in plasma IL-6 levels ( Figure 1D ). To address whether increased IL-1b secretion was restricted to challenge with the TLR4 agonist LPS or whether this was a more general phenomenon, we also injected mice of either genotype with the TLR9 agonist CpG-ODN or Listeria monocytogenes. Figure 1E ), and it decreased plasma levels of IL-1b, TNF-a, and IL-6 ( Figures 1F-1H ). In comparison, inhibition of TNF-a signaling through administration of soluble TNFa receptor (Etanercept) (Suffredini et al., 1995) was less efficient in reducing LPS toxicity in Ikkb Dmye mice, although it completely protected Ikkb F/F controls ( Figure 1G ). Unlike Anakinra, Etanercept did not reduce plasma IL-1b in Ikkb Dmye mice ( Figure 1H ), suggesting that IL-1b was the key inflammatory mediator in LPS-challenged Ikkb Dmye mice. In addition, the initial signaling by IL-1b may be responsible for the further increase in secretion of IL-1b and other cytokines.
Because IKKb is deleted in both macrophages and neutrophils in Ikkb Dmye mice, we examined which cell type contributed to increased plasma IL-1b levels after LPS application. We used clodronate-containing liposomes (van Rooijen et al., 1997) and Gr-1 antibody (RB6-8C5) (Vassiloyanakopoulos et al., 1998) to deplete macrophages and neutrophils, respectively. Flow cytometry of splenocytes or peritoneal exudates, as well as immunohistochemical staining for the macrophage marker F4/80 in spleen and liver sections, confirmed efficient depletion of macrophages and Kupffer cells in Ikkb Dmye mice and control mice without affecting Gr-1 + cells ( Figure S3 ). Macrophage depletion improved survival in LPS-treated Ikkb Dmye mice (Figure 2A ), and substantially decreased plasma IL-1b and TNF-a ( Figures 2B and 2C ). Successful neutrophil depletion by anti-Gr-1 administration, as confirmed on blood smears (data not shown), both rendered Ikkb Dmye mice significantly more resistant to LPS-induced toxicity than Ikkb F/F controls ( Figure 2D ) and inhibited IL-1b release ( Figure 2E ), whereas the effect on plasma TNF-a was less pronounced ( Figure 2F ). Thus, both neutrophils and macrophages contribute to IL-1b release and mortality in LPS-challenged Ikkb Dmye mice. Nonetheless, it should be recognized that the Gr-1 antibody used may also deplete Gr-1 + CD11b + F4/80 + '' inflammatory monocytes'' that are also likely to contribute to IL-1b release (Taylor and Gordon, 2003) .
The affect of IKKb-deficient neutrophils on IL-1b release after endotoxin challenge was further examined in another mouse mutant, the previously characterized Mx1-Cre x Ikkb F/F mouse, called Ikkb D (Ruocco et al., 2005) . In these mice induction of Mx1-Cre by systemic injection of the interferon (IFN) inducer poly(I:C) (Kuhn et al., 1995) results in IKKb deletion in IFN-responsive cells, including all myeloid cells . Ikkb D mice exhibited neutrophilia within the first 14 days after the first poly(I:C) injection, which was not only sustained, but became more extensive over time ( Figures 3A-3D ). This resembles observations made in mice transplanted with fetal liver cells from Ikkb À/À or Rela À/À mice (Horwitz et al., 1997; Senftleben et al., 2001) , indicating a role for NF-kB-dependent mechanisms in neutrophil homeostasis. Importantly, LPS administration to Ikkb D mice caused 100% mortality within 24 hr ( Figure 3E ), and it increased plasma IL-1b levels dramatically, with a >40-fold increase over LPStreated Ikkb Dmye mice (compare Figure 1B with Figure 3F ), which do not display neutrophilia (data not shown). Yet, similar to Ikkb Dmye mice, survival of Ikkb D mice was markedly improved by inhibition of IL-1b with IL-1ra ( Figure S4 ).
These results demonstrate the importance of the neutrophils' contribution to elevated plasma-IL-1b in endotoxin-challenged myeloid IKKb-deficient mice, and confirm that IL-1b is responsible for increased mortality in these animals.
Enhanced IL-1b Release by IKKb-Deficient Macrophages and Neutrophils Is Mediated by Distinct Mechanisms To investigate the mechanisms underlying the unexpected increase in plasma IL-1b and TNF-a, we prepared bone marrow-derived macrophages (BMDMs) from Ikkb D mice. These cells were highly compromised in LPSinduced NF-kB activation ( Figure S5 ) and showed decreased pro-IL-1b and TNF-a mRNA induction ( Figure 4A ), which was paralleled by reduced levels of pro-IL-1b and pro-TNF-a, and decreased TNF-a release ( Figures 4B  and 4D ). However, despite reduced pro-IL-1b expression, LPS treatment of Ikkb D macrophages resulted in more IL-1b secretion than did the same treatment of NF-kBcompetent Ikkb F/F cells ( Figure 4C ). Immunoblot analysis revealed that the IL-1b secreted by Ikkb D macrophages was properly processed ( Figure 4D ). Thus, Ikkb D macrophages show the expected decrease in pro-IL-1b mRNA synthesis, but due to very efficient pro-IL-1b processing, they secrete much more IL-1b than control macrophages.
IKKb-deficient macrophages are also more susceptible to LPS-induced apoptosis than normal cells . To investigate whether increased macrophage apoptosis, which can result in caspase-1 activation, contributed to enhanced release of IL-1b, as proposed previously (Hogquist et al., 1991) , we employed the pan-caspase inhibitor Z-VAD-fmk and the general serine protease inhibitor TPCK, both of which inhibit apoptosis in IKKb-deficient macrophages . Both inhibitors were equally or more effective than the caspase-1 inhibitor Ac-YVAD-cmk, used as a positive control in these experiments, in inhibiting IL-1b secretion ( Figure 4E ), suggesting that enhanced IL-1b processing in IKKb-deficient macrophages is due to enhanced apoptosis and caspase-1 activation. Indeed, Ikkb
Dmye macrophages exhibited higher levels of activated caspase-3 ( Figure 4B ) and secreted more activated caspase-1 than control macrophages ( Figure 4F ) while expressing normal amounts of intracellular pro-caspase-1 ( Figure S6) .
One of the NF-kB-dependent antiapoptotic genes in macrophages is the serpin plasminogen activator inhibitor 2 (PAI-2), which is not expressed in THP1 cells, a human myelomonocytic cell line in which LPS treatment alone (without cotreatment with ATP) results in IL-1b secretion (Martinon et al., 2002; Park et al., 2005) . Reintroduction of PAI-2 into Ikkb D macrophages inhibited LPS-induced apoptosis, as judged by annexin V staining, and completely blocked LPS-induced IL-1b secretion ( Figure 4G) . These results directly demonstrate that the product of an NF-kB regulated gene serves as a negative regulator of caspase-1-dependent IL-1b secretion. Recently, while this work was under revision, Bruey et al. demonstrated that another NF-kB-dependent antiapoptotic gene product, Bcl-x L , is also a negative regulator of IL-1b secretion (Bruey et al., 2007) .
We next turned to neutrophils to determine whether IL-1b processing is also enhanced in these cells in the absence of IKKb. Thioglycollate-elicited peritoneal neutrophils were purified and examined for IL-1b and TNF-a expression and release. Immunoblot analysis corroborated efficient deletion of IKKb in Ikkb D neutrophils and inhibition of LPS-induced NF-kB activation ( Figure S7 ). To examine whether loss of IKKb affects neutrophil function, we measured chemotaxis and bactericidal activity. Whereas chemotactic activity was increased in Ikkb D neutrophils ( Figure S7D ), we could not observe any differences between the two genotypes in their capacity to kill live E. coli within 8 hr after infection ( Figure S7E ). Interestingly, plasma IL-1b levels were also increased in E. coliinfected Ikkb D mice ( Figure S7 ). As in macrophages, we found reduced LPS-induced IL-1b and TNF-a mRNA in Ikkb D neutrophils ( Figure 5A ). Intracellular pro-IL-1b levels were downregulated as well ( Figure 5B ), though to an even greater extent than in macrophages ( Figure 4B ). Nonetheless, supernatants of Ikkb D neutrophils contained more immunoreactive IL-1b than those of Ikkb F/F cells ( Figure 5C ), paralleling the results in macrophages. TNF-a secretion, however, was decreased as expected ( Figure 5D ).
To examine if increased IL-1b release by IKKb-deficient neutrophils was also associated with enhanced apoptosis, we analyzed annexin V staining, which marks apoptotic cells, of Gr-1 + neutrophils before and after ex vivo LPS stimulation. In sharp contrast to macrophages, the number of apoptotic neutrophils was lower before and after LPS stimulation (especially at earlier time points) when cells were obtained from Ikkb D mice instead of Ikkb F/F mice ( Figure 5E ). Likewise, no difference in caspase-3 activation could be detected between Ikkb F/F and Ikkb D neutrophils 24 hr after LPS addition ( Figure 5F ). Thus, in neutrophils, IKKb deficiency attenuates apoptosis and may therefore account for the neutrophilia observed in Ikkb D mice. Unlike macrophages in which LPS-induced IL-1b secretion was diminished in the absence of caspase-1, neutrophils from caspase-1 À/À mice did not exhibit reduced bioactive IL-1b secretion after LPS stimulation ( Figure 5G ), as confirmed by an IL-1b bioassay ( Figure 5H ). Taken together, these data suggest that an IKKb-regulated, caspase-1-independent mechanism of IL-1b processing accounts for IL-1b release by neutrophils.
Enhanced Serine Protease Activity in IKKb-Deficient Neutrophils Proteinase 3 (PR3), neutrophil elastase (NE), and cathepsin G (CatG) are the main serine proteases of azurophilic granules of neutrophils (Pham, 2006) , and may play a role in IL-1b and TNF-a release (Coeshott et al., 1999) . We therefore examined whether these enzymes are activated in IKKb-deficient neutrophils and if their activation might be linked to IL-1b processing. MeOSuc-AAPVpNA is a high-affinity substrate for NE and murine PR3 (Wiesner et al., 2005) that can be used to measure the activity of NE and PR3 in mice. Hydrolysis of MeOSuc-AAPV-pNA was markedly elevated in lysates of Ikkb D neutrophils, even without LPS stimulation ( Figure 6A ). To distinguish between NE and PR3, we used recombinant secretory leukoprotease inhibitor (SLPI), an inhibitor of NE and CatG that does not block PR3 (Wiesner et al., 2005) . SLPI blocked MeOSuc-AAPV-pNA hydrolysis by $50% in lysates of Ikkb D neutrophils, but a similar degree of inhibition was also seen in Ikkb F/F control neutrophils, suggesting that NE activity is only partially responsible for elevated IL-1b processing in IKKb-deficient neutrophils. The nonspecific serine protease inhibitor 3, 4-dichloroisocoumarin (3, 4-DCIC) completely blocked protease activity, confirming the enzymatic specificity of the assay results ( Figure 6A ). To determine whether enhanced enzyme activity was due to increased expression, we examined PR3 protein levels, but found them to be only modestly (2-fold) upregulated in Ikkb D neutrophils ( Figure 6B ). RNA analysis of PR3, NE, and CatG confirmed this modest upregulation ( Figure S8 ). Because the 2-fold increase in PR3 expression cannot account for the 5-fold increase in protease activity, PR3 enzymatic activity is also increased in IKKb-deficient neutrophils. To determine which serpin could be responsible for this increased activity, we examined the RNA and protein expression of various serpins, some of which are known to be regulated by NF-kB. Interestingly, of these, serpin B1 (monocyte neutrophil elastase inhibitor [MNEI] ) showed an increased expression in Ikkb D neutrophils, suggesting a compensatory mechanism. However, similarly to macrophages, PAI-2 expression was absent in Ikkb D neutrophils, suggesting its involvement in PR3 regulation.
We next determined whether PR3 or another serine protease is a major contributor to enhanced IL-1b processing in IKKb-deficient neutrophils. Neutrophils were treated or not with different protease inhibitors and stimulated with LPS, and IL-1b in culture supernatants was assayed. Immunoblot analysis revealed that in IKKb-proficient neutrophils, the majority of secreted IL-1b was unprocessed pro-IL-1b, whereas in supernatants of Ikkb D neutrophils, most of the immunoreactive IL-1b was the processed form, whose release was inhibited by the different protease inhibitors ( Figure 6C ). To confirm that NE and PR3 can process pro-IL-1b, we produced pro-IL-1b in HEK293 cells and incubated it with purified NE or PR3 ( Figures 6D and  6E ). PR3 efficiently and dose-dependently processed pro-IL-1b to IL-1b, and was clearly more potent than NE. Formation of mature, bioactive IL-1b was confirmed by a bioassay ( Figure 6F ). Importantly, administration of MeOSuc-AAPV-cmk completely protected Ikkb D mice from LPS-induced lethality ( Figure 6G ) and led to a dramatic decrease in plasma IL-1b and TNF-a ( Figures 6H  and 6I ). Administration of a1-anti-trypsin, a potent inhibitor of extracellular, but not intracellular, NE and PR3, did not improve survival and did not decrease IL-1b plasma levels (data not shown). The caspase-1 inhibitor Ac-YVADcmk was not as efficient in protecting Ikkb D mice from LPS-induced lethality as MeOSuc-AAPV-cmk. Although MeOSuc-AAPV-cmk did not affect macrophage apoptosis (data not shown), we cannot rule out certain off-target effects of this inhibitor, and as discussed below, the initial PR3-dependent (or a different protease-dependent) IL-1b release by IKKb-deficient neutrophils may trigger caspase-1-mediated IL-1b processing by IKKb-deficient macrophages. Overall, increased intracellular serine protease activity, particularly PR3 and to a lesser extent NE, in IKKb-deficient granulocytes can account for increased IL-1b release by these cells.
To evaluate whether PR3 activity is regulated directly by NF-kB rather than by other IKKb functions (Wegener et al., 2006) , we isolated neutrophils from Mx1-Cre x Rela F/F mice, called Rela D , which produce a RelA protein that lacks its nuclear localization signal (NLS) and part of the transactivation domain, and are therefore functionally deficient for NF-kB p65/RelA (Algü l et al., 2007) . Like Ikkb D neutrophils, Rela D neutrophils also displayed enhanced serine protease activity and continued to secrete IL-1b despite diminished pro-IL-1b expression levels ( Figure S9 ). These results indicate that defective NF-kB activation can account for increased serine protease activity and IL-1b secretion in IKKb-deficient neutrophils.
Pharmacological IKKb Inhibition also Results in Neutrophilia and LPS Sensitivity In Ikkb
Dmye and Ikkb D mice, IKKb is absent in specific cell types responsible for TNF-a and IL-1b production during endotoxin challenge. However, NF-kB is activated normally in other cells (Greten et al., 2004; Maeda et al., 2005) . This situation may not fully mimic a potential therapeutic intervention with a systemically active inhibitor, which is likely to target all cells. We therefore also employed a pharmacological approach using the selective IKKb inhibitor ML120B (Nagashima et al., 2006) . ML120B effectively inhibited IKKb and NF-kB activation in myeloid cells ( Figure S10 ), but its short-term administration to wild-type mice had little impact on LPS-induced mortality ( Figure 7A ). Plasma IL-1b levels were increased, whereas levels of circulating TNF-a were dramatically decreased ( Figures 7B and 7C) .
Administration of ML120B for several days leads to granulocytosis (Nagashima et al., 2006) , resembling the phenotype of Ikkb D mice. We therefore examined whether repetitive ML120B treatment augmented LPS sensitivity. Wild-type mice were given ML120B twice daily (300 mg/kg each time) for 4 days and development of neutrophilia was confirmed in blood smears (data not shown). Similar to Ikkb D mice, ML120B-treated animals were much more susceptible to LPS-induced mortality than untreated mice ( Figure 7D ). Plasma IL-1b was dramatically upregulated, whereas the initial LPS-induced surge in plasma TNF-a was suppressed (Figures 7E and 7F) . Thus, prolonged IKKb inhibition increases susceptibility to endotoxin-induced shock and mortality by enhancing IL-1b processing.
DISCUSSION
IKKb-dependent NF-kB activation is considered to play a major role in the transcriptional control of acute and chronic inflammation (Bonizzi and Karin, 2004) , suggesting that IKKb inhibitors may be effective anti-inflammatory drugs . Unexpectedly, and counterintuitively, inhibition of this central pathway enhances susceptibility to endotoxin-induced shock and mortality by augmenting IL-1b processing and secretion. These findings stand in sharp contrast to the marked ability of IKKb inhibition to prevent TNF-a expression and release, an endpoint that raised enthusiasm for targeting IKKb in chronic inflammatory diseases such as rheumatoid arthritis and inflammation-induced bone loss (McIntyre et al., 2003; Ruocco et al., 2005) . Thus, in addition to revealing an unanticipated role for IKKb-dependent NF-kB activation as a negative regulator of pro-IL-1b processing, our results raise serious concerns about the long-term impact of IKKb inhibition. However, it is possible that enhanced IL1b processing may occur only upon acute septic infection, where, as discussed below, it is likely to play a protective role, and we suggest ways to avoid such complications. It should also be noted that partial and transient inhibition of IKKb does not seem to be as problematic.
Prolonged inhibition of NF-kB, however, leads to enhanced processing of pro-IL-1b, despite a profound transcriptional inhibition of NF-kB-dependent gene expression, including inhibition of IL-1b gene transcription. Whereas NF-kB positively regulates a major transcriptional control point in inflammation and innate immunity (Ghosh and Karin, 2002) , the regulation of pro-IL-1b (and pro-IL-18) processing acts as a control of innate immunity and inflammation at the posttranscriptional level (Martinon and Tschopp, 2004) . Regulation of secretion differs from that of most other cytokines, as IL-1b does not contain a signal peptide and its production and release depend on transcriptional and posttranscriptional processes (Dinarello, 2005; Martinon and Tschopp, 2004; Ogura et al., 2006) . The majority of IL-1b induced upon endotoxin challenge in an NF-kB-dependent manner remains in the cell as pro-IL-1b, and the picogram amounts of IL-1b released by myeloid cells activated by (A-C) Survival and corresponding IL-1b and TNF-a plasma levels of LPS-challenged WT mice given 300 mg/kg of the IKKb inhibitor ML120B by oral gavage 1 hr prior to LPS administration (30 mg/kg). (D) Survival and corresponding IL-1b (E) and TNF-a (F) plasma levels in WT mice given 300 mg/kg ML120B by oral gavage twice daily for 4 days before LPS challenge. (G) Schematic representation of the proposed dual role of IKKb-dependent NF-kB activation in regulation of IL-1b secretion by macrophages and neutrophils: in neutrophils, which appear to be a rapid, but minor (albeit critical), source of IL-1b, IKKb-driven NF-kB positively regulates the transcription of pro-IL-1b mRNA and serine protease inhibitor genes whose products inhibit the activity of PR3, which can process pro-IL-1b. Secretion of biologically active IL-1b by neutrophils acts together with LPS to augment IL-1b secretion by macrophages, which represent the major source of this cytokine. In the macrophage, NF-kB controls pro-IL-1b mRNA synthesis as well as the expression of genes such as PAI-2, Bcl-x L , and ICEBERG, whose products inhibit caspase-1 activation. Data are averages of at least four animals per time point. Error bars = SEM.
LPS alone are small compared with nanogram amounts of TNF-a or IL-6. Whereas NF-kB is the main transcription factor controlling IL-1b gene induction, caspase-1 is the major protease required for pro-IL-1b processing, especially in macrophages (Kuida et al., 1995; Li et al., 1995) . Akin to NF-kB, whose activation depends on the signalresponsive IKK complex (Ghosh and Karin, 2002) , also termed the signalsome (Mercurio et al., 1997) , caspase-1 is regulated by the inflammasome, a group of related protein complexes which can respond to different ligands (Martinon and Tschopp, 2004; Ogura et al., 2006) . However, several other proteases, including NE, PR3, CatG, chymase, and chymotrypsin, as well as certain matrix metalloproteinases, were shown to be capable of cleaving pro-IL-1b at critical sites involved in generation and secretion of the bioactive molecule (Black et al., 1988; Dinarello et al., 1986; Hazuda et al., 1990; Irmler et al., 1995; Mizutani et al., 1991) . It was speculated that these enzymes, once secreted, cleave pro-IL-1b extracellularly, thereby amplifying the inflammatory reaction (Fantuzzi et al., 1997) . Our results strongly suggest that although the majority of IL-1b in mice lacking NF-kB activity in myeloid cells is derived from excessive caspase-1 activation in macrophages, neutrophils (and inflammatory monocytes) also play an important role in excessive IL-1b release, perhaps by augmenting its release from macrophages ( Figure 7G ). In neutrophils lacking IKKb, IL-1b is secreted through a caspase-1-independent mechanism. In these cells intracellular serine proteases, especially PR3, are involved in IL-1b processing and secretion. In support of this, pretreatment of Ikkb D mice with purified a1-anti-trypsin, which inhibits extracellular serine proteases (Liu et al., 2000) , did not reduce IL-1b secretion, but a cell-permeable peptide specifically blocking NE and PR3 reduced IL-1b production substantially and protected Ikkb D mice from endotoxin-induced death. Nonetheless, we cannot rule out off-target effects of this particular inhibitor, MeOSuc-AAPV-cmk, and a caspase-1 inhibitor, Ac-YVAD-cmk, also blocked excessive IL-1b secretion.
We tried to determine which cell type is responsible for enhanced IL-1b release after IKKb or NF-kB depletion or inhibition in myeloid cells. We found that in LPSchallenged Ikkb Dmye mice, depletion of either neutrophils (and inflammatory monocytes) or macrophages was protective, suggesting critical involvement of all these cell types. Similar results were observed with the use of protease inhibitors. Both the caspase-1 inhibitor Ac-YVAD-cmk and the PR3 inhibitor MeOSuc-AAPV-cmk led to an almost complete inhibition of IL-1b secretion in Ikkb D mice ( Figures 6H and 6K) . However, caspase-1 activity is required for IL-1b processing and secretion only in macrophages. In vitro, IKKb-deficient macrophages secrete much more (7-to 10-fold) IL-1b per cell cell after LPS stimulation than IKKb-deficient neutrophils under the same conditions. Furthermore, in vitro treatment with an IKKb inhibitor readily augments caspase-1 activation and IL-1b secretion by LPS-treated macrophages ( Figure 4F ), and caspase-1 inhibition prevents IL-1b secretion. These results suggest that the major IL-1b producers under these conditions are the macrophages; yet, depletion of neutrophils (and inflammatory monocytes) via a strategy that leaves the macrophages intact also results in substantial inhibition of massive IL-1b secretion. To reconcile these results, we suggest that the initial and more rapid release of IL-1b by IKKb-deficient neutrophils may augment the delayed and more substantial IL-1b secretion by IKKbdeficient macrophages ( Figure 7G ). In support of this hypothesis, administration of an inhibitor of IL-1b signaling (IL-1ra) also inhibits IL-1b secretion ( Figure 1F) .
It was previously found that caspase-1 activation is enhanced by macrophage apoptosis (Hogquist et al., 1991) . Macrophage apoptosis is increased in the absence of NF-kB due to defective expression of A1/Bfl-1 and PAI-2, which are encoded by NF-kB target genes . It is well established that in addition to these genes, NF-kB controls expression of genes that encode direct caspase inhibitors (Karin and Lin, 2002) . Such molecules may inhibit caspase-1 activation both directly and indirectly by suppressing macrophage apoptosis. In human cells, NF-kB may also regulate expression of ICEBERG, which appears to be a dedicated inhibitor of inflammasome activation (Humke et al., 2000) . In addition, while this manuscript was under revision, it was shown that Bcl-x L , which is encoded by an NF-kB target gene, and its relative Bcl-2 directly inhibit caspase-1 activation by NALP1 (Bruey et al., 2007) . In neutrophils, production of IL-1b depends not on caspase-1 but mainly on serine proteases, whose activity is also negatively regulated by NFkB. It was documented that expression of several serine protease inhibitors (serpins), including PAI-2, MNEI, and proteinase inhibitor 9 (PI-9) is transcriptionally activated by NF-kB (Kannan-Thulasiraman and Shapiro, 2002; Park et al., 2005; Zeng and Remold-O'Donnell, 2000) . Of these, PAI-2 expression is dramatically reduced in IKKbdeficient neutrophils and macrophages and restoration of PAI-2 expression in IKKb-deficient macrophages inhibits LPS-induced IL-1b secretion. However, the direct target for PAI-2 that is involved in control of IL-1b processing is currently unknown.
Repetitive administration of a specific IKKb inhibitor mimicked the effect of myeloid IKKb deletion despite efficient inhibition of NF-kB-mediated gene induction, including pro-TNF-a and pro-IL-1b synthesis. We suggest that the high stability of pro-IL-1b may account for its accumulation over time, even when pro-IL-1b mRNA synthesis is inhibited. It is also plausible that the translational efficiency of pro-IL-1b mRNA may be increased once its levels drop below a certain threshold. In vitro, treatment of macrophages with an IKKb inhibitor strongly augments LPS-induced caspase-1 activation and obliterates the need for a second signal, such as high concentrations of ATP.
Collectively, our results illustrate that, quite unexpectedly, IKKb and NF-kB are also involved in negative regulation of inflammasome activation. It is well established that inflammation is a potentially dangerous, but protective, response that is controlled by numerous negative feedback mechanisms (Cohen, 2002; Karin et al., 2006) . While many of these negative regulators act transcriptionally by targeting NF-kB or IKK, our work reveals additional negative regulatory mechanisms that act posttranscriptionally through inhibition of pro-IL-1b processing. However, it is also possible that the major goal of the negative regulatory mechanisms we unraveled is to augment host defense rather than inhibit inflammation. Since certain highly virulent pathogens have evolved the ability to inhibit NF-kB activation and thereby evade NF-kB-dependent innate immunity (Orth et al., 2000) , the augmented secretion of IL-1b by NF-kB-deficient myeloid cells may provide a compensatory mechanism that allows activation of an additional, NF-kB-independent, host defense response.
Undoubtedly, the mechanistic details of IL-1b production and its regulation by NF-kB also need to be assessed in normal human macrophages and neutrophils. Until then, our results raise serious concerns about possible complications associated with long-term inhibition of NF-kB. Although pharmacological inhibition is unlikely to be as complete as genetic disruption, it may cause loss of innate immunity and augment acute inflammation associated with septic infections.
EXPERIMENTAL PROCEDURES Mice
Ikkb
Dmye , Ikkb D , and Ikkb F/F mice have been described (Greten et al., 2004; Ruocco et al., 2005) . To delete IKKb in Ikkb D mice, 250 mg poly(I:C) (Sigma) was injected i.p. 2 weeks before LPS administration or isolation of myeloid cells. Generation of Rela F/F mice is described elsewhere (Algü l et al., 2007) . Four to six mice of each genotype were i.p. injected with LPS (E. coli O111:B4, Sigma), CpG-DNA (ODN1668), or E. coli (serotype O111:K58), or injected i.v. with L. monocytogenes wild-type (10403S). Etanercept (Enbrel, Amgen), Ac-YVAD-cmk (Calbiochem), and MeOSuc-AAPV-cmk (Calbiochem) were given i.p. 1 hr before LPS administration. Anakinra (Kineret, Amgen) was injected subcutaneously every 4 hr over a period of 12 hr. ML120B (Nagashima et al., 2006) was given by oral gavage either once before LPS or twice daily over 4 days. Clodronate-liposomes and RB6-8C5 were applied i.p. 24 hr before LPS. Liposome-encapsulated clodronate (a kind gift of Roche Diagnostics GmbH, Mannheim, Germany) was prepared as previously described (Van Rooijen and Sanders, 1994) .
Isolation of Macrophages and Neutrophils
BMDMs were generated as described (Greten et al., 2004) . To isolate neutrophils, mice were i.p. injected with 1 ml of 3% thioglycollate (DIFCO) and peritoneal cells were flushed out 3-5 hr later. After blocking Fc-receptors with anti-CD16/32 (Becton & Dickinson), cells were incubated with PE-labeled Gr-1 antibody (Becton & Dickinson) and magnetically separated using anti-PE beads according to the manufacturer's (Miltenyi Biotec) instructions. Retroviral reconstitution was performed essentially as described (Miething et al., 2007) . Bone marrow was transduced with EGFP-PAI-2 retrovirus and EGFP + cells were sorted by flow cytometry. EGFP + and EGFP À cells were differentiated into macrophages and stimulated with LPS.
Protein and RNA Analysis IL-1b and TNF-a in plasma and cell supernatants were measured using the DuoSet ELISA systems (R&D Systems) according to manufacturer's instructions. RNA was extracted using Trizol (Invitrogen). RNase Protection Assay (RPA) was performed as described . cDNA synthesis, real-time PCR, immunoblot, and Electrophoretic Mobility Shift Assay (EMSA) were as described (Greten et al., 2004) . Primer sequences are available upon request. Antibodies recognizing IL-1b, TNF-a (R&D Systems), IL-1b (for Immunoprecipitation [IP] ) and cleaved caspase-3 (Becton & Dickinson), b-actin (Sigma), IKKb (UBI), RelA, IkBa, and PR3 (Santa Cruz) were purchased from the indicated suppliers.
Protease Activity Determination and Inhibition Cell pellets were lysed and hydrolysis of MeOSuc-AAPV-pNA (Calbiochem) was determined in 0.05 M NaH 2 PO 4 , 0.1 M NaCl, 0.005 % Triton X-100, and 5% DMSO at 405 nm. For inhibition experiments rhSLPI (R&D Systems) and 3, 4-DCIC (Calbiochem) were used.
In Vitro Processing of pro-IL-1b and IL-1b Bioassay HEK293 cells were transfected with pro-IL-1b expression plasmid and cells were lysed after 24 hr. Lysates were incubated with purified NE and PR3 (Athens Research & Technology) for 30 min. IL-1b bioassay was performed using EL-4 cells, which were stimulated for 24 hr. IL-2 release by EL-4 cells was measured by an ELISA (eBioscience) according to manufacturer's instructions.
Chemotaxis Assay Neutrophils (1 3 10 6 ) were seeded in transwell plates and incubated in the presence of 10 mM fMLP in the lower chamber for 60 min, after which cells in the lower chamber were counted.
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